164 related articles for article (PubMed ID: 14556779)
1. Receptor tyrosine kinases in normal and malignant haematopoiesis.
Reilly JT
Blood Rev; 2003 Dec; 17(4):241-8. PubMed ID: 14556779
[TBL] [Abstract][Full Text] [Related]
2. FLT3 and its role in the pathogenesis of acute myeloid leukaemia.
Reilly JT
Leuk Lymphoma; 2003 Jan; 44(1):1-7. PubMed ID: 12691136
[TBL] [Abstract][Full Text] [Related]
3. Flt3 receptor tyrosine kinase as a drug target in leukemia.
Schmidt-Arras D; Schwäble J; Böhmer FD; Serve H
Curr Pharm Des; 2004; 10(16):1867-83. PubMed ID: 15180525
[TBL] [Abstract][Full Text] [Related]
4. Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.
Kiyoi H; Naoe T
Int J Hematol; 2006 May; 83(4):301-8. PubMed ID: 16757428
[TBL] [Abstract][Full Text] [Related]
5. Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases.
Verstraete K; Savvides SN
Nat Rev Cancer; 2012 Nov; 12(11):753-66. PubMed ID: 23076159
[TBL] [Abstract][Full Text] [Related]
6. Molecular regulation of receptor tyrosine kinases in hematopoietic malignancies.
Correll PH; Paulson RF; Wei X
Gene; 2006 Jun; 374():26-38. PubMed ID: 16524673
[TBL] [Abstract][Full Text] [Related]
7. [Mutations of the gene coding for the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Significance as the disease-specific molecular marker for diagnosis, prognosis and innovative therapy approaches].
Spiekermann K; Hiddemann W; Schnittger S
Dtsch Med Wochenschr; 2005 Apr; 130(16):1020-5. PubMed ID: 15830315
[No Abstract] [Full Text] [Related]
8. Tyrosine kinase receptors as attractive targets of cancer therapy.
Bennasroune A; Gardin A; Aunis D; Crémel G; Hubert P
Crit Rev Oncol Hematol; 2004 Apr; 50(1):23-38. PubMed ID: 15094157
[TBL] [Abstract][Full Text] [Related]
9. Flt3 in acute myelogenous leukemia: biology, prognosis, and therapeutic implications.
Voutsadakis IA
Med Oncol; 2003; 20(4):311-24. PubMed ID: 14716027
[TBL] [Abstract][Full Text] [Related]
10. Receptor tyrosine kinases: from biology to pathology.
Choura M; Rebaï A
J Recept Signal Transduct Res; 2011 Dec; 31(6):387-94. PubMed ID: 22040163
[TBL] [Abstract][Full Text] [Related]
11. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.
Drexler HG
Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433
[TBL] [Abstract][Full Text] [Related]
12. FLT-3: a new focus in the understanding of acute leukemia.
Markovic A; MacKenzie KL; Lock RB
Int J Biochem Cell Biol; 2005 Jun; 37(6):1168-72. PubMed ID: 15778081
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic receptors of class III receptor-type tyrosine kinases.
Rosnet O; Birnbaum D
Crit Rev Oncog; 1993; 4(6):595-613. PubMed ID: 7506935
[TBL] [Abstract][Full Text] [Related]
14. FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors.
Gilliland DG
Best Pract Res Clin Haematol; 2003 Sep; 16(3):409-17. PubMed ID: 12935959
[TBL] [Abstract][Full Text] [Related]
15. In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor.
Zhao M; Kiyoi H; Yamamoto Y; Ito M; Towatari M; Omura S; Kitamura T; Ueda R; Saito H; Naoe T
Leukemia; 2000 Mar; 14(3):374-8. PubMed ID: 10720129
[TBL] [Abstract][Full Text] [Related]
16. Normal and oncogenic FLT3.
Naoe T; Kiyoi H
Cell Mol Life Sci; 2004 Dec; 61(23):2932-8. PubMed ID: 15583855
[TBL] [Abstract][Full Text] [Related]
17. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells.
Rosnet O; Bühring HJ; Marchetto S; Rappold I; Lavagna C; Sainty D; Arnoulet C; Chabannon C; Kanz L; Hannum C; Birnbaum D
Leukemia; 1996 Feb; 10(2):238-48. PubMed ID: 8637232
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic receptor tyrosine kinase in leukemia.
Mizuki M; Ueda S; Matsumura I; Ishiko J; Schwäble J; Serve H; Kanakura Y
Cell Mol Biol (Noisy-le-grand); 2003 Sep; 49(6):907-22. PubMed ID: 14656048
[TBL] [Abstract][Full Text] [Related]
19. FLT3 in human hematologic malignancies.
Kiyoi H; Naoe T
Leuk Lymphoma; 2002 Aug; 43(8):1541-7. PubMed ID: 12400596
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.
Kaitsiotou H; Keul M; Hardick J; Mühlenberg T; Ketzer J; Ehrt C; Krüll J; Medda F; Koch O; Giordanetto F; Bauer S; Rauh D
J Med Chem; 2017 Nov; 60(21):8801-8815. PubMed ID: 28991465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]